<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00741663</url>
  </required_header>
  <id_info>
    <org_study_id>318P</org_study_id>
    <nct_id>NCT00741663</nct_id>
  </id_info>
  <brief_title>Spironolactone Versus Spironolactone Plus Furosemide (SVSSF)</brief_title>
  <acronym>SVSSF</acronym>
  <official_title>Phase 4 Study on the Comparison Between Combined Versus Sequential Diuretic Treatment of Moderate Ascites in Nonazotemic Patients With Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Padova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Padova</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The question whether the sequential diuretic therapy, that means using an antialdosteronic
      drug at first and adding a loop diuretic in nonresponders, is better than the combination of
      the two diuretics from the beginning (combined diuretic therapy) in the treatment of ascites
      in patients with cirrhosis is still open. Therefore, the aim of the study is to compare
      sequential versus combined diuretic therapy in these patients. One hundred patients will be
      randomized into two groups. Group A will receive potassium canrenoate at the initial dose of
      200 mg/day, then increased up to 400 mg/day. Non responders will be treated with 400 mg/day
      of potassium canrenoate and furosemide at an initial dose of 50 mg/day, then increased up to
      150 mg/day. Group B will receive at first 200 mg/day of potassium canrenoate and 50 mg/day of
      furosemide, then increased up to 400 mg/day and 150 mg/day, respectively.

      The percentage of responders to dthe diuretic treatment, the time to get the resolution of
      ascites and the rate of adverse effects will be compared between the two Groups of Patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the percentage of responders to the diuretic treatment; the percentage of patients who develop adverse effects to diuretics</measure>
    <time_frame>within three weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>the percentage of patients who will respond to the diuretic treatment, the percentage of patients who will develop adverse effects to diuretics</measure>
    <time_frame>within three weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to get the response to diuretics</measure>
    <time_frame>within three weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Ascites</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone and furosemide</intervention_name>
    <description>Patients in arm A will receive potassium canrenoate at the initial dose of 200 mg/day, then increased up to 400 mg/day. Non responders will be treated with 400 mg/day of potassium canrenoate and furosemide at an initial dose of 50 mg/day, then increased up to 150 mg/day.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone and furosemide</intervention_name>
    <description>Patients in arm B will receive at first 200 mg/day of potassium canrenoate and 50 mg/day of furosemide, then increased up to 400 mg/day and 150 mg/day, respectively.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Grade 2 ascites

          -  Serum creatinine less than 1.2 mtg/dl

          -  Serum sodium &gt; 130 mmol/l

          -  Serum potassium within 3.5 and 4.5 mmol/l

          -  At least five days after the withdrawal of diuretics

          -  A 90 mmol/day Na diet.

        Exclusion Criteria:

          -  Any therapeutic paracentesis for ascites before inclusion

          -  Cardiac or respiratory disease

          -  Gastrointestinal bleeding, hepatic encephalopathy, bacterial infections in the last 4
             weeks before inclusion.

          -  The use of NSAIDs or other nephrotoxic drugs in the last 4 weeks before inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Padova, Dept. of Clinical and Experimental Medicine</name>
      <address>
        <city>Padova</city>
        <zip>35100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Santos J, Planas R, Pardo A, Durández R, Cabré E, Morillas RM, Granada ML, Jiménez JA, Quintero E, Gassull MA. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety. J Hepatol. 2003 Aug;39(2):187-92.</citation>
    <PMID>12873814</PMID>
  </results_reference>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2008</study_first_submitted>
  <study_first_submitted_qc>August 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2008</study_first_posted>
  <last_update_submitted>September 24, 2008</last_update_submitted>
  <last_update_submitted_qc>September 24, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2008</last_update_posted>
  <responsible_party>
    <name_title>Prof. Paolo Angeli</name_title>
    <organization>Dept. of Clinical and Experimental Medicine</organization>
  </responsible_party>
  <keyword>cirrhosis</keyword>
  <keyword>ascites</keyword>
  <keyword>diuretic therapy</keyword>
  <keyword>potassium canrenoate</keyword>
  <keyword>furosemide</keyword>
  <keyword>hyperkalemia</keyword>
  <keyword>plasma renin activity</keyword>
  <keyword>nitric oxide</keyword>
  <keyword>serum sodium concentration</keyword>
  <keyword>refractory ascites</keyword>
  <keyword>Nonazotemic patients with cirrhosis and moderate ascites</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
    <mesh_term>Diuretics</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
    <mesh_term>Canrenoic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

